{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T08:50:30Z","timestamp":1782377430770,"version":"3.54.5"},"reference-count":47,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.clinthera.2026.03.004","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T11:28:49Z","timestamp":1775474929000},"page":"407-417","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comprehensive Ethnicity Assessment of Ribociclib Pharmacokinetics in Patients With Early and Advanced Breast Cancer"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9569-0574","authenticated-orcid":false,"given":"Yan","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Zarate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Shen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2026.03.004_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clinthera.2026.03.004_bib0002","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106(5):dju055","author":"Howlader","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clinthera.2026.03.004_bib0003","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/jnci\/djn305","article-title":"Effects of reproductive and demographic changes on breast cancer incidence in China: a modeling analysis","volume":"100","author":"Linos","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clinthera.2026.03.004_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103835","article-title":"Current and future burden of breast cancer in Asia: a GLOBOCAN data analysis for 2022 and 2050","volume":"79","author":"Fu","year":"2025","journal-title":"Breast"},{"key":"10.1016\/j.clinthera.2026.03.004_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101541","article-title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"8","author":"Im","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.clinthera.2026.03.004_bib0006","unstructured":"Kisqali (ribociclib). Prescribing Information. Basel, Switzerland: Novartis Pharmaceuticals Corporation; 2025."},{"key":"10.1016\/j.clinthera.2026.03.004_bib0007","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.03.004_bib0008","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.03.004_bib0009","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall survival with ribociclib plus endocrine therapy in breast cancer","volume":"381","author":"Im","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.03.004_bib0010","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall survival with ribociclib plus fulvestrant in advanced breast cancer","volume":"382","author":"Slamon","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.03.004_bib0011","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3","volume":"36","author":"Slamon","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2026.03.004_bib0012","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2026.03.004_bib0013","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u24c7) for Breast Cancer V.1.2026. \u00a9 National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed January 26, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"key":"10.1016\/j.clinthera.2026.03.004_bib0014","unstructured":"European Society for Medical Oncology. ESMO-MCBS Scorecard Ribociclib (MONALEESA-2). Accessed January 14, 2026. https:\/\/www.esmo.org\/guidelines\/esmo-mcbs\/esmo-mcbs-for-solid-tumours\/esmo-mcbs-scorecards?scorecard=9."},{"key":"10.1016\/j.clinthera.2026.03.004_bib0015","unstructured":"European Society for Medical Oncology. ESMO-MCBS Scorecard Ribociclib (MONALEESA-3). Accessed January 14, 2026. https:\/\/www.esmo.org\/guidelines\/esmo-mcbs\/esmo-mcbs-for-solid-tumours\/esmo-mcbs-scorecards?scorecard=161."},{"key":"10.1016\/j.clinthera.2026.03.004_bib0016","unstructured":"European Society for Medical Oncology. ESMO-MCBS Scorecard Ribociclib (MONALEESA-7). Accessed January 14, 2026. https:\/\/www.esmo.org\/guidelines\/esmo-mcbs\/esmo-mcbs-for-solid-tumours\/esmo-mcbs-scorecards?scorecard=158."},{"key":"10.1016\/j.clinthera.2026.03.004_bib0017","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.annonc.2025.04.006","article-title":"ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0)","volume":"36","author":"Cherny","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2026.03.004_bib0018","unstructured":"European Society for Medical Oncology. ESMO-MCBS Scorecard Ribociclib (NATALEE). Accessed January 14, 2026. https:\/\/www.esmo.org\/guidelines\/esmo-mcbs\/esmo-mcbs-for-solid-tumours\/esmo-mcbs-scorecards\/scorecard-468-1."},{"key":"10.1016\/j.clinthera.2026.03.004_bib0019","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s40262-023-01338-z","article-title":"Use of pharmacokinetic and pharmacodynamic data to develop the CDK4\/6 inhibitor ribociclib for patients with advanced breast cancer","volume":"63","author":"Ji","year":"2024","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2026.03.004_bib0020","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.599","article-title":"An integrated assessment of the ADME properties of the CDK4\/6 inhibitor ribociclib utilizing preclinical in vitro, in vivo, and human ADME data","volume":"8","author":"James","year":"2020","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.clinthera.2026.03.004_bib0021","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/jcph.1825","article-title":"Pharmacokinetics of ribociclib in subjects with hepatic impairment","volume":"61","author":"Samant","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2026.03.004_bib0022","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4103\/2229-3485.86874","article-title":"Implications of ICH-E5: assessment of drug's sensitivity to ethnic factors and necessity of a bridging study for global drug development","volume":"2","author":"Gupta","year":"2011","journal-title":"Perspect Clin Res"},{"key":"10.1016\/j.clinthera.2026.03.004_bib0023","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.890","article-title":"Inter-ethnic differences in pharmacokinetics-is there more that unites than divides?","volume":"9","author":"Olafuyi","year":"2021","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.clinthera.2026.03.004_bib0024","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/cas.13428","article-title":"Phase I study of single-agent ribociclib in Japanese patients with advanced solid tumors","volume":"109","author":"Doi","year":"2018","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clinthera.2026.03.004_bib0025","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2026.03.004_bib0026","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1158\/1078-0432.CCR-16-1248","article-title":"A phase I study of the cyclin-dependent kinase 4\/6 inhibitor ribociclib (LEE011) in patients with advanced solid tumors and lymphomas","volume":"22","author":"Infante","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"15","key":"10.1016\/j.clinthera.2026.03.004_bib0027","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1200\/JCO.2016.34.15_suppl.568","article-title":"Ribociclib (LEE011) and letrozole in estrogen receptor-positive (ER+), HER2-negative (HER2\u2013) advanced breast cancer (aBC): phase Ib safety, preliminary efficacy and molecular analysis","volume":"34","author":"Juric","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2026.03.004_bib0028","doi-asserted-by":"crossref","first-page":"e7408","DOI":"10.1002\/cam4.7408","article-title":"Initial ribociclib plus endocrine therapy for HR+\/HER2- advanced breast cancer in pre- and postmenopausal Chinese women: primary results from a phase 2 randomized study","volume":"13","author":"Shao","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.clinthera.2026.03.004_bib0029","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231178125","article-title":"Rationale and trial design of NATALEE: a phase III trial of adjuvant ribociclib\u2009+\u2009endocrine therapy versus endocrine therapy alone in patients with HR+\/HER2- early breast cancer","volume":"15","author":"Slamon","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.clinthera.2026.03.004_bib0030","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1111\/cas.14554","article-title":"Ribociclib, a CDK 4\/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer","volume":"111","author":"Yap","year":"2020","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clinthera.2026.03.004_bib0031","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus endocrine therapy in early breast cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.03.004_bib0032","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.annonc.2021.05.353","article-title":"Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival","volume":"32","author":"Slamon","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2026.03.004_bib0033","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1158\/1078-0432.CCR-21-3032","article-title":"Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+\/HER2- advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial","volume":"28","author":"Lu","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2026.03.004_bib0034","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/clpt.2008.141","article-title":"The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies","volume":"84","author":"Yasuda","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2026.03.004_bib0035","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1093\/annonc\/mdu042","article-title":"Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies","volume":"25","author":"Chan","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2026.03.004_bib0036","series-title":"Drug Discovery and Development: From Targets and Molecules to Medicines","first-page":"297","article-title":"Pharmacokinetics: theory and application in drug discovery and development","author":"Sharma","year":"2021"},{"key":"10.1016\/j.clinthera.2026.03.004_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.hnm.2025.200304","article-title":"Effect of food components on cytochrome P450 expression and activity","volume":"40","author":"Sang","year":"2025","journal-title":"Human Nutr Metab"},{"key":"10.1016\/j.clinthera.2026.03.004_bib0038","first-page":"10","article-title":"Pharmacokinetic interactions between herbal medicines and drugs: their mechanisms and clinical relevance","author":"Rombol\u00e0","year":"2020","journal-title":"Life (Basel)"},{"key":"10.1016\/j.clinthera.2026.03.004_bib0039","article-title":"Effect of green tea extract and soy isoflavones on the pharmacokinetics of rosuvastatin in healthy volunteers","volume":"9","author":"Zeng","year":"2022","journal-title":"Front Nutr"},{"key":"10.1016\/j.clinthera.2026.03.004_bib0040","unstructured":"National Medical Products Administration (China) Center for Drug Evaluation. Ribociclib succinate tablets (JXHS2200089) marketing application technical review report. In Chinese. https:\/\/www.cde.org.cn\/main\/xxgk\/postmarketpage?acceptidCODE=4cceb0ffbbb9f9b160fc8c9c3d6734792023."},{"key":"10.1016\/j.clinthera.2026.03.004_bib0041","unstructured":"National Medical Products Administration (China). Drug evaluation information disclosure: drug evaluation approval results. 2025. Accessed December 2025. https:\/\/www.nmpa.gov.cn\/zwfw\/sdxx\/sdxxyp\/yppjfb\/20250521151427103.html."},{"key":"10.1016\/j.clinthera.2026.03.004_bib0042","doi-asserted-by":"crossref","first-page":"e1143","DOI":"10.1002\/onco.13811","article-title":"Evaluation of the association of polymorphisms with palbociclib-induced neutropenia: pharmacogenetic analysis of PALOMA-2\/-3","volume":"26","author":"Iwata","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.clinthera.2026.03.004_bib0043","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s12282-019-00970-7","article-title":"Neutropenia management with palbociclib in Japanese patients with advanced breast cancer","volume":"26","author":"Masuda","year":"2019","journal-title":"Breast Cancer"},{"key":"10.1016\/j.clinthera.2026.03.004_bib0044","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.3389\/fphar.2019.01235","article-title":"Strategies for early prediction and timely recognition of drug-induced liver injury: the case of cyclin-dependent kinase 4\/6 inhibitors","volume":"10","author":"Raschi","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2026.03.004_bib0045","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/jcph.1856","article-title":"Ribociclib Population Pharmacokinetics and Pharmacokinetic\/Pharmacodynamic Analysis of Neutrophils in Cancer Patients","volume":"61","author":"Lu","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2026.03.004_bib0046","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/clpt.2014.129","article-title":"Functional gene variants of CYP3A4","volume":"96","author":"Werk","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2026.03.004_bib0047","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/jcph.2310","article-title":"Quantitative assessment of ribociclib exposure-response relationship to justify dose regimen in patients with advanced breast cancer","volume":"63","author":"Ji","year":"2023","journal-title":"J Clin Pharmacol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826000664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826000664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T08:32:55Z","timestamp":1782376375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291826000664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0149291826000664"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.03.004","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive Ethnicity Assessment of Ribociclib Pharmacokinetics in Patients With Early and Advanced Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}